| Ms Dana Emerson Basu, PSYD | |
|
2549 Eastbluff Dr # 134, Newport Beach, CA 92660-3500 | |
| (608) 575-2111 | |
| (949) 220-7004 |
| Full Name | Ms Dana Emerson Basu |
|---|---|
| Gender | Female |
| Speciality | Psychologist - Clinical |
| Location | 2549 Eastbluff Dr # 134, Newport Beach, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023267549 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | PSY24579 (California) | Primary |
| Entity Name | Avalon Medical Development Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346250347 PECOS PAC ID: 1850283995 Enrollment ID: O20040721000841 |
News Archive
Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.
Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.
Researchers from the Department of Biomedical Research of the University of Bern and the University Clinic of Visceral Surgery and Medicine of the Inselspital Bern, Switzerland, have discovered that changes in the composition of the intestinal bacteria in patients with chronic inflammatory bowel disease affect the severity of the disease and the success of therapy.
A fingerprint test published today in AACC's Clinical Chemistry journal can tell whether someone has taken heroin or cocaine, and accurately distinguishes between drug users versus individuals who were exposed to drug residue in the environment.
› Verified 1 days ago
| Entity Name | Avalon Medical Development Corporation |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1346250347 PECOS PAC ID: 1850283995 Enrollment ID: O20061104000281 |
News Archive
Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.
Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.
Researchers from the Department of Biomedical Research of the University of Bern and the University Clinic of Visceral Surgery and Medicine of the Inselspital Bern, Switzerland, have discovered that changes in the composition of the intestinal bacteria in patients with chronic inflammatory bowel disease affect the severity of the disease and the success of therapy.
A fingerprint test published today in AACC's Clinical Chemistry journal can tell whether someone has taken heroin or cocaine, and accurately distinguishes between drug users versus individuals who were exposed to drug residue in the environment.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Dana Emerson Basu, PSYD 2549 Eastbluff Dr # 134, Newport Beach, CA 92660-3500 Ph: (608) 575-2111 | Ms Dana Emerson Basu, PSYD 2549 Eastbluff Dr # 134, Newport Beach, CA 92660-3500 Ph: (608) 575-2111 |
News Archive
Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.
Enobia Pharma Inc. unveiled findings from the first hypophosphatasia self-reported patient survey intended to evaluate the burden of illness associated with HPP at the 2010 American College of Medical Genetics Annual Clinical Genetics Meeting.
Researchers from the Department of Biomedical Research of the University of Bern and the University Clinic of Visceral Surgery and Medicine of the Inselspital Bern, Switzerland, have discovered that changes in the composition of the intestinal bacteria in patients with chronic inflammatory bowel disease affect the severity of the disease and the success of therapy.
A fingerprint test published today in AACC's Clinical Chemistry journal can tell whether someone has taken heroin or cocaine, and accurately distinguishes between drug users versus individuals who were exposed to drug residue in the environment.
› Verified 1 days ago
Margaret Mary Decker, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1600 Dove St, Suite 140, Newport Beach, CA 92660 Phone: 949-922-1529 Fax: 949-809-5779 | |
Dr. Paul T Depompo, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 4060 Campus Dr, Suite 120, Newport Beach, CA 92660 Phone: 949-300-1952 Fax: 949-313-1723 | |
Dr. Jacqueline A Josephson, PSY.D Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1400 Quail St Ste 136, Newport Beach, CA 92660 Phone: 510-686-3306 | |
Ghada Al-seilawi, EDUCATIONAL PSYCHOLO Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1001 Dove St Ste 270, Newport Beach, CA 92660 Phone: 949-432-4815 | |
Dr. Vance B Becker, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1451 Quail St, Ste 102, Newport Beach, CA 92660 Phone: 949-757-1113 Fax: 949-757-1114 | |
Dr. Carey Sherilyn Incledon, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1101 Dove St Ste 190, Newport Beach, CA 92660 Phone: 949-630-0630 Fax: 949-688-5577 |